Vasopressin during abdominal hysterectomy: a randomized controlled trial.
OBJECTIVE
To investigate if the use of vasopressin during abdominal hysterectomy would decrease blood loss.


METHODS
Fifty-one patients undergoing abdominal hysterectomy with the diagnosis of leiomyomatous uterus were randomized and received either vasopressin 10 units/10 mL of normal saline or 10 mL of normal saline, injected 5 mL bilaterally, 1 cm medial to the uterine vessels into the lower uterine segment. The sample size was determined assuming a one-third reduction in total blood loss would be clinically relevant. A power analysis determined that 25 patients would be required in each group to assure a power of 0.80, at the.05 significance level.


RESULTS
Overall, the two groups were very similar with regard to their demographics, preoperative diagnosis, and relevant findings at the time of surgery. The mean total blood loss in the vasopressin and placebo groups was 445.41 mL and 748.42 mL, respectively. Total blood loss was significantly decreased by 40% in the vasopressin group compared with the placebo group (P <.001). There was no statistically significant difference between the two groups with respect to possible confounding variables or surgical complications.


CONCLUSIONS
Injection of vasopressin into the uterus at the time of abdominal hysterectomy significantly reduces blood loss without increasing morbidity. We have shown that it is a useful adjunct during abdominal hysterectomy.
Okin
C R
CR
University of Pittsburgh, Magee-Women's Hospital, Pittsburgh, Pennsylvania 15213, USA.
Guido
R S
RS
Meyn
L A
LA
Ramanathan
S
S
D000293:Adolescent; D000328:Adult; D016063:Blood Loss, Surgical / Q000517:prevention & control*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007044:Hysterectomy / Q000379:methods*; D015552:Injections, Intralesional; D007889:Leiomyoma / Q000175:diagnosis / Q000601:surgery*; D008875:Middle Aged; D011336:Probability; D012016:Reference Values; D012494:Sampling Studies; D016896:Treatment Outcome; D014594:Uterine Neoplasms / Q000175:diagnosis / Q000601:surgery*; D014662:Vasoconstrictor Agents / Q000008:administration & dosage*; D014667:Vasopressins / Q000008:administration & dosage*
D014662:Vasoconstrictor Agents; D014667:Vasopressins